Pharmvista Inc. – Trademark Portfolio
Entity Type: 03
Pharmvista Inc. holds 20 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 16 filings in this category. The portfolio also extends into Class 45 (Legal & Security Services) across 4 Nice Classification classes. Currently, 11 trademarks are registered. Notable registered marks include MELAT-8, ORGALAX, DAILYCAL, TURMERICA, and DIGESTYN-7. The owner is based in East Hanover, NJ.
17 West Street
East Hanover, NJ 07936
Showing of trademarks Trademarks
Trademark Classifications
Pharmvista Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Legal services; security services for the protection of property and individuals
Machines and machine tools; motors and engines; machine coupling and transmission components
Frequently Asked Questions
How many trademarks does Pharmvista Inc. have?
Pharmvista Inc. has 20 U.S. trademarks filed with the USPTO. Of these, 11 registered, 2 abandoned, 7 cancelled.
What trademark classes does Pharmvista Inc. file in?
Pharmvista Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 45 (Legal & Security Services), Class 7 (Machinery), Class 40 (Treatment & Processing). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Pharmvista Inc.'s most well-known trademarks?
Pharmvista Inc.'s registered trademark portfolio includes well-known marks such as MELAT-8, ORGALAX, DAILYCAL, TURMERICA, and DIGESTYN-7. These are among 11 currently registered trademarks in the portfolio.
What is Pharmvista Inc.'s trademark registration success rate?
Pharmvista Inc. has a 55% trademark registration rate, with 11 out of 20 resolved applications resulting in successful registration. Currently, 0 applications are pending review.